Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immediate versus deferred switch from boosted protease inhibitor to dolutegravir in virologically suppressed HIV-infected patients
2013-003704-39Phase 4Completed
- Sponsor
- St Stephen's AIDS Trust
- Start
- Mar 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of dolutegravir in human immunodeficiency virus infection (HIV) (2 arms), sponsored by St Stephen's AIDS Trust. Primary endpoint: Maintenance of virological suppression at week 48. Started Mar 2014; status: completed.
02
Drugs
dolutegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2013-003704-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003704-39.